{
    "Trade/Device Name(s)": [
        "Access Thyroglobulin"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240927",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220972"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MSW"
    ],
    "Summary Letter Date": "June 28, 2024",
    "Summary Letter Received Date": "April 4, 2024",
    "Submission Date": "June 20, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Thyroglobulin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "DxI 9000 Access Immunoassay Analyzer",
        "Access 2 Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescent detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Diluent",
        "Substrate",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for Access Thyroglobulin chemiluminescent immunoassay for quantitative determination of thyroglobulin in serum and plasma using Access Immunoassay Systems",
    "Indications for Use Summary": "Intended to aid in monitoring for the presence of persistent or recurrent/metastatic disease in patients with differentiated thyroid cancer who have had thyroid surgery and lack serum thyroglobulin antibodies",
    "fda_folder": "Immunology"
}